Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sarah Heringer

Showing results (11-20 of 14) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 14 results.
Vaccine|November 2, 2023
Immunogenicity and reactogenicity of a first booster with BNT162b2 or full-dose mRNA-1273: A randomised VACCELERATE trial in adults ≥75 years (EU-COVAT-1)Julia M Neuhann, Jannik Stemler, Antonio J Carcas, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|July 11, 2024
Immunogenicity, reactogenicity, and safety of a second booster with BNT162b2 or full-dose mRNA-1273: A randomized VACCELERATE trial in adults aged ≥75 years (EU-COVAT-1-AGED Part B)Jannik Stemler, Lusine Yeghiazaryan, Christoph Stephan, et al.
Vaccines|December 23, 2023
The Challenges of Vaccine Trial Participation among Underserved and Hard-to-Reach Communities: An Internal Expert Consultation of the VACCELERATE ConsortiumDimitrios Poulimeneas, Markela Koniordou, Dimitra Kousi, et al.
Vaccine|June 6, 2022
VACCELERATE Volunteer Registry: A European study participant database to facilitate clinical trial enrolmentJon Salmanton-García, Fiona A Stewart, Sarah Heringer, et al.
Pageof 2

Showing results (11-20 of 14) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 14 results.
Vaccine|November 2, 2023
Immunogenicity and reactogenicity of a first booster with BNT162b2 or full-dose mRNA-1273: A randomised VACCELERATE trial in adults ≥75 years (EU-COVAT-1)Julia M Neuhann, Jannik Stemler, Antonio J Carcas, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|July 11, 2024
Immunogenicity, reactogenicity, and safety of a second booster with BNT162b2 or full-dose mRNA-1273: A randomized VACCELERATE trial in adults aged ≥75 years (EU-COVAT-1-AGED Part B)Jannik Stemler, Lusine Yeghiazaryan, Christoph Stephan, et al.
Vaccines|December 23, 2023
The Challenges of Vaccine Trial Participation among Underserved and Hard-to-Reach Communities: An Internal Expert Consultation of the VACCELERATE ConsortiumDimitrios Poulimeneas, Markela Koniordou, Dimitra Kousi, et al.
Vaccine|June 6, 2022
VACCELERATE Volunteer Registry: A European study participant database to facilitate clinical trial enrolmentJon Salmanton-García, Fiona A Stewart, Sarah Heringer, et al.
Pageof 2